| Co-Investigator(Kenkyū-buntansha) |
KITAYAMA Joji Univ. of Tokyo Hospital/lecturer, 医学部・附属病院, 講師 (20251308)
TAKAMIZAWA Masaru Univ. of Tokyo Hospital/lecturer, 医学部・附属病院, 講師 (40216784)
SHIBATA Yoichi Univ. of Tokyo Hospital/Prof., 医学部・附属病院, 教授 (30010474)
TSUNO Nelson Univ. of Tokyo Hospital/Assistant, 医学部・附属病院, 助手 (50282637)
|
|---|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2000: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 1999: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Research Abstract |
In the present examination, it was possible to establish a cytotoxic T lymphocyte by introducing mRNA extracted from human colon cancer cell line into the human dendritic cell, and coculturing with T lymphocyte in in vitro. It was shown that this CTL selectively killed only the cell line from which the introduced RNA was extracted. And, the induction efficiency of CTL, when it was compared in the case in which Liposome was used and case in which it was not used, though it was evaluated of Liposome, as it is efficient a little, no significant difference could be observed. Though the efficiency of the mRNA recovery from the human surgery specimen was examined, the yield point was greatly influenced in fixation situation of samples as estimated, and mRNA was also generally fragmented. Therefore, it seemed not to be effective to introduce RNA extracted from these fixed specimen into dendritic cells. On the contrary, freezing samples seemed to be suitable as a material for this method, since mRNA was abounding on the yield point, and since the fragmentation was also little. Based on the present examination, it was shown that by extracting mRNA not only from large specimen of surgical sample but also from small samples such as the biopsy piece, it is possible to make dendritic cell vaccine which presented the tumor antigens specific to the patient's tumor. These results indicate further adaptation extension of the dendritic cell therapy.
|
